Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Calls For Improved Education On Biosimilars

White Paper Finds Biosimilars Still Not Clearly Understood By Stakeholders

Executive Summary

Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.

You may also be interested in...



Communication Needed To Avoid Biosimilar ‘Nocebo’ Effect

Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential ‘nocebo’ effect, insisted Professor Fabrizio Benedetti at a EULAR symposium.

Tambe Moves Up To Lead Biocon Biologics

Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.

Leonard Resignation Leaves AAM Looking For New Leadership

Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel